A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Prior treatment

• Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor or Apatinib.For exploratory cohort ，patients who received PARP inhibitor are eligible;
• Radiation or anti-hormonal therapy or anticancer therapy within 14 days before first administration;
• Patients with clinical symptoms of cancer ascites, pleural effusion, who need to drainage, or who have undergone ascites drainage within 3 months prior to the first administration;

Other illness

• Known active hepatitis C virus, or known active hepatitis B virus;

Age

• Prior malignancy unless curatively treated and disease-free for \> 5 years prior to study entry. Prior adequately treated non-melanoma skin cancer, in situ cancer of the cervix allowed;

Other

• Known to be human immunodeficiency virus positive;
• Untreated and/or uncontrolled brain metastases;
• Pregnant or breast-feeding women.

• Histologically diagnosed high-grade serous or endometrioid recurrent ovarian,fallopian tube,or peritoneal cancer.
• Patients must have received at least 2 previous platinum-containing regimens.
• At least one target lesion.
• ECOG performance status 0-1.
• Adequate bone marrow, kidney and liver function.